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Malaria-related hemophagocytic lymphohistiocytosis is a rare, potentially fatal, hyperinflam-
matory disease entity which can be challenging to diagnose and treat. It is usually associated
with Plasmodium falciparum infection. It is less frequently associated with Plasmodium vivax.
Here we report an unusual case of a 23-year-old healthy Nigerian man who presented with
fever, microangiopathic hemolytic anemia, acute renal failure, and confusion, and was diag-
nosed as having cerebral malaria-related hemophagocytic lymphohistiocytosis caused by
P. vivax infection. He was successfully treated with intravenous artesunate and doxycycline
with dramatic clinical improvement.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Malaria continues to remain a major health burden world-
wide. According to the World Malaria Report 2015, the esti-mated number of malaria cases was 214 million and the
number of deaths was 438,000 in 2015 alone [1]. The World
Health Organization defines cerebral malaria as a clinical
syndrome caused by Plasmodium falciparum infection man-
ifesting as coma (defined with Glasgow Coma Scale of less
than 11 in adults and Blantyre Coma Scale of less than 3 in
children) persisting for more than 30 minutes after termina-
tion of seizure and no other cause of explanation for the
coma [2]. Another rare complication of malaria ishttp://dx.
2 S. Amireh et al.hemophagocytic lymphohistiocytosis (HLH), which is a syn-
drome characterized by multisystem inflammation that
results from prolonged and excessive activation of the anti-
gen presenting cells (macrophages and histocytes) and CD8+
T cells that leads to phagocytosis of hematopoietic cells [3].
HLH compromises two different conditions: (1) the primary
(familial) form that is usually seen during infancy or child-
hood; and (2) the secondary HLH which results from an
excessive immune reaction to infections, autoimmune dis-
orders, or malignancy.
Case report
A 23-year-old healthy Nigerian man was brought to the
emergency department with symptoms of relapsing fever,
confusion, and lethargy ongoing for 5 days. Past medical his-
tory and family history were unremarkable. He had not
taken any medications. On physical examination, the
patient was stuporous with a Glasgow Coma Scale of 10;
he did not have neck stiffness or focal neurological signs.
He had splenomegaly and scleral icterus. His vital signs were
as follows: blood pressure of 119/70 mmHg, heart rate of
119 bpm, temperature of 39.2 C, and a respiratory rate of
24 breaths per minute.
Laboratory workup revealed a platelet count of
19,000 cells/mL, hemoglobin of 7.9 g/dL, total white cell
count of 5,600 cells/mL, and reticulocyte count of 10.0%.
Biochemical tests were as follows: total bilirubin of
15.5 mg/dL, direct bilirubin of 13.5 mg/dL, alkaline phos-
phatase of 206 IU/L, aspartate transaminase of 123 IU/L,
alanine transaminase of 96 IU/L, lactic acid dehydrogenase
of 2,023 IU/L, lactate of 4.2 mmol/L, blood urea nitrogen
of 28 mg/d:, creatinine of 1.13 mg/dL, and normal elec-
trolytes. Other investigation results were as follows:
D-dimer of 6,369 mg/L, haptoglobin of <8 mg/dL, fibrinogen
of 508 mg/dL, ferritin of 4,622 mg/L, fasting triglycerides
level of 322 mg/dL, and soluble interleukin-2 receptorTable 1 Clinicopathological characteristics and data of our pati
(HLH) diagnosed as per the HLH 2004 criteria.
HLH 2004 diagnostic criteria Pati
Fever P38.5 C Fev
Splenomegaly Pre
Peripheral blood cytopenia, with at least 2 of the
following: hemoglobin <9 g/dL (for infants <4 wk,
hemoglobin <10 g/dL); platelets <100,000/lL; absolute
neutrophil count <1000/lL
Plat
Hypertriglyceridemia (fasting triglycerides >265 mg/dL)
&/or hypofibrinogenemia (fibrinogen <150 mg/dL)
Trig
Hemophagocytosis in bone marrow, spleen, lymph node,
or liver
N/A
Low or absent NK cell activity N/A
Ferritin >500 ng/mL Ferr
Elevated soluble CD25 (soluble IL-2 receptor a) Solu
Note: IL-2 = interleukin-2; N/A = not applicable; wk = weeks.
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710 U/mL). Prothrombin time and activated partial throm-
bin time were in normal range, Direct antiglobulin test
was negative, and two sets of blood cultures and urine cul-
tures were all negative. Serology test for hepatitis A, B, and
C viruses, cytomegalovirus, Epstein–Barr virus, and human
immune deficiency virus were also negative. Abdominal
computed tomography scan showed hepatosplenomegaly,
and computed tomography scan of the head along with
the chest X-ray were normal. Lumbar puncture was not per-
formed due to the patient’s low platelet count. Thick and
thin blood smears showed ring forms and trophozoites of
Plasmodium vivax. Polymerase chain reaction of the blood
confirmed the patient had P. vivax infection.
Given the patient’s clinical presentation, the findings on
the blood smear, and the fact that he met six out of eight
hemophagocytic lymphohistiocytosis diagnostic criteria
(Table 1), the diagnosis of cerebral malaria due to P. vivax,
complicated by HLH was established.
Treatment with intravenous quinidine and doxycycline
was initiated. After 24 hours of initiating treatment, the
patient’s mental status improved drastically and returned
to baseline. Quinidine was discontinued because of QTC pro-
longation and the patient was started on atovaqoune–pro-
guanil. On the 3rd day of hospitalization, the patient’s
mental status deteriorated again and he developed acute
renal failure with a creatinine level of 5.22 mg/dL and a
blood urea nitrogen level of 80 mg/dL. Given the glomerular
filtration rate of 17 mL/min and the relapse of the patient’s
mental status, atovaqoune–proguanil was discontinued and
the US Center of Disease Control and Prevention was con-
tacted to obtain artesunate that was delivered and initiated
on the same day. Over the course of the following 2 days,
the patient completed his artesunate course and his mental
status returned to normal again. However, his kidney func-
tion continued to worsen, which prompted the initiation of
hemodialysis. Three daily consecutive blood smears that
were done after completing treatment with artesunateent with malaria-related hemophagocytic lymphohistiocytosis
ent’s clinical & lab criteria
er 39.2 C
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cycline for a total of 14 days. Eventually the patient’s kid-
ney function started to improve so hemodialysis was
stopped. After a total of 15 days of hospitalization, the
patient was discharged in a stable state with normalization
of his laboratory results including his blood counts.
Discussion
For many years, P. vivax was considered as a more benign
infection compared with P. falciparum, but recent reports
have documented the association of severe syndromes and
death with P. vivax. In one retrospective study that ana-
lyzed the data collected from all the malaria cases reported
to the US Center of Disease Control and Prevention between
1985 and 2011, 0.9% of P. falciparum cases resulted in death
and 9.3% were classified as severe, whereas 0.09% of
P. vivax cases resulted in death and 1.3% were classified
as severe [4]. While pulmonary dysfunction due to respira-
tory distress, pulmonary embolism, and acute respiratory
distress syndrome are the main reasons for mortality in
P. vivax, other complications like cerebral malaria, bleed-
ing, severe anemia, liver dysfunction, and renal failure are
the main reasons for mortality in P. falciparum [5].
Both cerebral malaria and HLH are uncommon syndromes
that can be associated with P. vivax infection and can lead
to death if not recognized and treated early. HLH is an
inflammatory syndrome that usually presents with fever,
cytopenias, hepatitis, and splenomegaly [6]. The pathogen-
esis of HLH is thought to be due to impaired function of nat-
ural killer cells, cytotoxic T cells, and T regulatory cells that
leads to an augmented activation of antigen presenting cells
(macrophages and histocytes) and CD8+ T cells, which in
turn leads to hemophagocytosis in the bone marrow and
the reticuloendothelial system. Elevated cytokines also play
a role in the syndrome which manifests in high levels of
interferon-c, interleukin-1, and interleukin-6 with the com-
pensatory downregulation of interleukin-10 [7]. According
to the HLH 2004 revised diagnostic guidelines published by
the Histocyte Society HLH Study Group, the diagnosis of
HLH can be made if either a molecular diagnosis consistent
with HLH is fulfilled, or if the patient meets at least five of
the following eight criteria (Table 1): (1) fever; (2) spleno-
megaly; (3) cytopenias affecting two or more of three lin-
eages in the peripheral blood; (4) hypertriglyceridemia of
more than 265 mg/dL or hypofibrinogenemia of less than
150 mg/dL; (5) hemophagocytosis in bone marrow, spleen,
or lymph nodes in the absence of evidence of malignancy;
(6) low or absent natural killer-cell activity; (7) ferritin of
more than 500 mg/dL; (8) elevated level of soluble CD25
(soluble interleukin-2 receptor) of more than 2,400 U/mL
[6].
HLH is classified in to two different conditions: primary
and secondary. The primary (familial) HLH usually presents
in infancy and early childhood, but can also present in
utero, adolescence, or adulthood [3,6]. Secondary HLH
may develop as a result of an infection, malignancy, or
autoimmune disorder [8]. The most common infections
associated with HLH are viral infections with Epstein–Barr
virus being the most common, and less commonly other her-
pes viruses (herpes simplex virus, varicella zoster, cytome-Please cite this article in press as: Amireh S et al., Severe Plasmodium viva
doi.org/10.1016/j.hemonc.2016.06.001galovirus, human herpesvirus 6, and human herpesvirus 8),
human immunodeficiency virus, adenovirus, hepatitis
viruses, parvo virus, and influenza. HLH has also been asso-
ciated with bacterial infections including mycobacteria and
spirochetes, fungal infections, and parasitic infections due
to Leishmenia donovani, P. falciparum, P. vivax, toxo-
plasma, babesiosis, and strongyloidiasis [8].
Our case is peculiar because it is the first reported case
in the US of a patient who not only presented with cerebral
malaria due to P. vivax, but also had HLH. Most of the case
reports of cerebral malaria have been reported in India.
These patients, like our patient, were successfully treated
with artesunate combination therapy with excellent out-
comes [9–11]. Patients with HLH due to infections can usu-
ally recover with supportive care and treating the
underlying infection. In our case, treating P. vivax with
artesunate combination therapy resulted in neurologic
recovery which obviated the need for dexamethasone, and
with continued supportive care the patient clinically
recovered.
Most cases of HLH caused by P. vivax have been reported
in South Korea [12–14] and India [15,16] and also achieved
complete recovery by treatment with an antimalarial regi-
men. Chemotherapy and immunosuppressant therapy with
dexamethasone, cyclosporine, and etopside may be indi-
cated in certain situations like familial HLH and severe
HLH particularly when associated with Epstein–Barr virus
infection [6].
P. vivax infection should always be suspected in patients
from endemic areas who present with symptoms of malaria.
Severe and persistent cytopenias with neurologic symptoms
should raise the possibility of a secondary HLH associated
with the infection. Early recognition and treatment are crit-
ical to prevent ominous outcomes.Conflicts of interest
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